Mary Sano

21.1k total citations · 8 hit papers
113 papers, 11.3k citations indexed

About

Mary Sano is a scholar working on Psychiatry and Mental health, Economics and Econometrics and Physiology. According to data from OpenAlex, Mary Sano has authored 113 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Psychiatry and Mental health, 26 papers in Economics and Econometrics and 24 papers in Physiology. Recurrent topics in Mary Sano's work include Dementia and Cognitive Impairment Research (55 papers), Health Systems, Economic Evaluations, Quality of Life (26 papers) and Alzheimer's disease research and treatments (19 papers). Mary Sano is often cited by papers focused on Dementia and Cognitive Impairment Research (55 papers), Health Systems, Economic Evaluations, Quality of Life (26 papers) and Alzheimer's disease research and treatments (19 papers). Mary Sano collaborates with scholars based in United States, United Kingdom and Canada. Mary Sano's co-authors include Michael Grundman, Ronald G. Thomas, Steven H. Ferris, Leon J. Thal, Eric Pfeiffer, Christopher Ernesto, Kimberly Schafer, Ronald J. Thomas, Shelia Jin and Carl W. Cotman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Mary Sano

108 papers receiving 10.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

1997 1.8k citations Mary Sano, Christopher Ernesto et al. profile →
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment

2005 1.3k citations Ronald G. Thomas, Michael Grundman et al. profile →
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease

1997 953 citations Mary Sano, Michael Grundman et al. Alzheimer Disease & Associated Disorders profile →
Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

2003 744 citations Paul Aisen, Kimberly Schafer et al. profile →
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.

2000 736 citations Ruth A. Mulnard, Carl W. Cotman et al. profile →
An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1997 683 citations Mary Sano, Christopher Ernesto et al. profile →
Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities.

1994 613 citations David W. Desmond, Yaakov Stern et al. profile →
evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease

2025 40 citations Jeffrey L. Cummings, Alireza Atri et al. Alzheimer s Research & Therapy profile →

Peers

Countries citing papers authored by Mary Sano

Since Specialization

Citations

This map shows the geographic impact of Mary Sano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Sano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Sano more than expected).

Fields of papers citing papers by Mary Sano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Sano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Sano. The network helps show where Mary Sano may publish in the future.

Co-authorship network of co-authors of Mary Sano

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Sano. A scholar is included among the top collaborators of Mary Sano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Sano. Mary Sano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease breakdown → 2025 ·Alzheimer s Research & Therapy ·Jeffrey L. Cummings, Alireza Atri, Howard Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León, Philip Scheltens	40
2	Cohen-mansfield agitation inventory total score as a measure of agitation and aggression in Alzheimer’s disease: A factor analysis 2025 ·International Psychogeriatrics ·Suzanne Hendrix, Mary Sano, Constantine G. Lyketsos, Paul B. Rosenberg, Anton P. Porsteinsson, Bruce L. Brown, William O. Dawson, Jeffrey L. Cummings	0
3	Recommendations for management and future investigation of psychosis in neurodegenerative disease: Findings from the International Psychogeriatric Association (IPA) working group 2025 ·International Psychogeriatrics ·(unknown), Corinne E. Fischer, Victor Abler, Byron Creese, (unknown), Adriana P. Hermida, Manabu Ikeda, Zahinoor Ismail, Dilip V. Jeste, Joanne McDermid, (unknown), (unknown), Susan Peschin, Anne Margriet Pot, Jacobo Mintzer, Mary Sano, (unknown), Clive Ballard	0
4	The Alzheimer's Association clinical practice guideline for the diagnostic evaluation, testing, counseling, and disclosure of suspected Alzheimer's disease and related disorders (DETeCD‐ADRD): Validated clinical assessment instruments 2024 ·Alzheimer s & Dementia ·Alireza Atri, Bradford C. Dickerson, Carolyn Clevenger, Jason Karlawish, David S. Knopman, Pei‐Jung Lin, Mary S. Norman, Chiadi U. Onyike, Mary Sano, (unknown), Marı́a C. Carrillo	7
5	The Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for specialty care 2024 ·Alzheimer s & Dementia ·Bradford C. Dickerson, Alireza Atri, Carolyn Clevenger, Jason Karlawish, David S. Knopman, Pei‐Jung Lin, Mary S. Norman, Chiadi U. Onyike, Mary Sano, (unknown), María C. Carrillo	19
6	Pandemic caregiving: Results from a survey of Alzheimer’s disease research center study partners 2023 ·Alzheimer s & Dementia ·Margaret Sewell, Judith Neugroschl, (unknown), (unknown), (unknown), (unknown), Carolyn W. Zhu, Mary Sano	1
7	Impact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease 2018 ·Alzheimer s & Dementia Translational Research & Clinical Interventions ·Ilana Belitskaya‐Lévy, Maurice W. Dysken, Peter Guarino, Mary Sano, Sanjay Asthana, Julia E. Vertrees, Muralidhar Pallaki, Maria D. Llorente, Susan Love, Gerard D. Schellenberg	9
8	A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease 2011 ·Neurology ·Mary Sano, Karen L. Bell, Douglas Galasko, James E. Galvin, Ronald G. Thomas, C H van Dyck, Paul Aisen	244
9	An update on treatment and prevention strategies for Alzheimer’s disease 2009 ·Current Neurology and Neuroscience Reports ·Judith Neugroschl, Mary Sano	41
10	The Effects of Patient Function and Dependence on Costs of Care in Alzheimer's Disease 2008 ·Journal of the American Geriatrics Society ·Carolyn W. Zhu, Christopher Leibman, Trent McLaughlin, Nikolaos Scarmeas, Marilyn Albert, Jason Brandt, Deborah Blacker, Mary Sano, Yaakov Stern	57
11	ADCS Prevention Instrument Project: Development of a Brief Verbal Memory Test for Primary Prevention Clinical Trials 2006 ·Alzheimer Disease & Associated Disorders ·David P. Salmon, Jeffrey L. Cummings, Shelia Jin, Mary Sano, Reisa A. Sperling, Edward Zamrini, Ronald C. Petersen, Steven D. Edland, Leon J. Thal, Steven H. Ferris	8
12	No Long-Term Effect of Behavioral Treatment on Psychotropic Drug Use for Agitation in Alzheimer's Disease Patients 2002 ·Journal of Geriatric Psychiatry and Neurology ·Myron Weiner, Rochelle E. Tractenberg, Mary Sano, Rebecca G. Logsdon, Linda Teri, Douglas Galasko, Anthony Gamst, (unknown), Leon J. Thal	19
13	Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial 2000 ·Obstetrical & Gynecological Survey ·Ruth A. Mulnard, Carl W. Cotman, Claudia H. Kawas, Christopher H. van Dyck, Mary Sano, Rachelle S. Doody, (unknown), Eric Pfeiffer, Shelia Jin, Anthony Gamst, Michael Grundman, Ronald G. Thomas	38
14	The Cognitive Syndrome of Vascular Dementia: Implications for Clinical Trials 1999 ·Alzheimer Disease & Associated Disorders ·David W. Desmond, Timo Erkinjuntti, Mary Sano, Jeffrey L. Cummings, John V. Bowler, Florence Pasquier, Joan T. Moroney, Steven H. Ferris, Yaakov Stern, Perminder S. Sachdev, (unknown)	22
15	Proxy-reported quality of life in Alzheimer's patients: Comparison of clinical and population-based samples. 1999 ·Steven M. Albert, (unknown), Diane M. Jacobs, Mary Sano, (unknown), (unknown), Scott A. Small, Yaakov Stern	32
16	A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimerʼs Disease Clinical Trials 1997 ·Alzheimer Disease & Associated Disorders ·Steven H. Ferris, Joan Mackell, Richard C. Mohs, Lon S. Schneider, Douglas Galasko, Peter J. Whitehouse, Frederick A. Schmitt, Mary Sano, Ronald G. Thomas, Christopher Ernesto, Michael Grundman, Kimberly Schafer, Leon J. Thal	37
17	Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs 1997 ·Alzheimer Disease & Associated Disorders ·Richard C. Mohs, David S. Knopman, Ronald C. Petersen, Steven H. Ferris, (unknown), Michael Grundman, Mary Sano, Linas A. Bieliauskas, David Geldmacher, Chris M. Clark, Leon J. Thal	495
18	Assessing Patterns of Agitation in Alzheimerʼs Disease Patients with the Cohen-Mansfield Agitation Inventory 1997 ·Alzheimer Disease & Associated Disorders ·Elisabeth Koss, Myron Weiner, Christopher Ernesto, Jiska Cohen‐Mansfield, Steven H. Ferris, Michael Grundman, Kimberly Schafer, Mary Sano, Leon J. Thal, Ronald G. Thomas, Peter J. Whitehouse	117
19	Multicenter Evaluation of New Instruments for Alzheimerʼs Disease Clinical Trials 1997 ·Alzheimer Disease & Associated Disorders ·Joan Mackell, Steven H. Ferris, Richard C. Mohs, Lon S. Schneider, Douglas Galasko, Peter J. Whitehouse, Frederick A. Schmitt, Mary Sano, Leon J. Thal	13
20	The Spanish Instrument Protocol 1997 ·Alzheimer Disease & Associated Disorders ·Mary Sano, Joan Mackell, Marcel O. Pontón, (unknown), J.L. Wilson, Sonia Pawluczyk, E. Pfeiffer, Ronald G. Thomas, Shelia Jin, Kimberly Schafer, (unknown), Michael Grundman, Steven H. Ferris, L. J. Thal	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact